| Chronic hepatitis C virus (HCV) disease burden and cost in the United States H Razavi, AC ElKhoury, E Elbasha, C Estes, K Pasini, T Poynard, ... Hepatology 57 (6), 2164-2170, 2013 | 646 | 2013 |
| Model for assessing human papillomavirus vaccination strategies EH Elbasha, EJ Dasbach, RP Insinga Emerging infectious diseases 13 (1), 28, 2007 | 620 | 2007 |
| Impact of vaccinating boys and men against HPV in the United States EH Elbasha, EJ Dasbach Vaccine 28 (42), 6858-6867, 2010 | 305 | 2010 |
| Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV … RP Insinga, EJ Dasbach, EH Elbasha BMC infectious diseases 9 (1), 119, 2009 | 296 | 2009 |
| Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature RP Insinga, EJ Dasbach, EH Elbasha Pharmacoeconomics 23 (11), 1107-1122, 2005 | 265 | 2005 |
| Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease EJ Dasbach, EH Elbasha, RP Insinga Epidemiologic reviews 28 (1), 88-100, 2006 | 229 | 2006 |
| A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations AB Gumel, EA Iboi, CN Ngonghala, EH Elbasha Infectious Disease Modelling 6, 148-168, 2021 | 223 | 2021 |
| Role of incidence function in vaccine-induced backward bifurcation in some HIV models O Sharomi, CN Podder, AB Gumel, EH Elbasha, J Watmough Mathematical Biosciences 210 (2), 436-463, 2007 | 215 | 2007 |
| On endogenous growth: the implications of environmental externalities EH Elbasha, TL Roe Journal of Environmental Economics and Management 31 (2), 240-268, 1996 | 171 | 1996 |
| Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits EH Elbasha, AB Gumel Bulletin of mathematical biology 68 (3), 577-614, 2006 | 153 | 2006 |
| Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance RP Insinga, G Perez, CM Wheeler, LA Koutsky, SM Garland, S Leodolter, ... Cancer Epidemiology, Biomarkers & Prevention 20 (2), 287-296, 2011 | 148 | 2011 |
| Vaccination against multiple HPV types EH Elbasha, AP Galvani Mathematical biosciences 197 (1), 88-117, 2005 | 146 | 2005 |
| Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives RP Insinga, EJ Dasbach, EH Elbasha, KL Liaw, E Barr Cancer Epidemiology Biomarkers & Prevention 16 (4), 709-715, 2007 | 133 | 2007 |
| Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation RP Insinga, EJ Dasbach, EH Elbasha, A Puig, LM Reynales-Shigematsu Vaccine 26 (1), 128-139, 2007 | 128 | 2007 |
| Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women RP Insinga, G Perez, CM Wheeler, LA Koutsky, SM Garland, S Leodolter, ... Cancer epidemiology, biomarkers & prevention 19 (6), 1585-1594, 2010 | 115 | 2010 |
| The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK EJ Dasbach, RP Insinga, EH Elbasha BJOG: An International Journal of Obstetrics & Gynaecology 115 (8), 947-956, 2008 | 107 | 2008 |
| An ex post economic impact assessment of planted forages in West Africa E Elbasha, PK Thornton, G Tarawali ILRI (aka ILCA and ILRAD), 1999 | 99* | 1999 |
| Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women RP Insinga, EJ Dasbach, EH Elbasha, KL Liaw, E Barr Infectious agents and cancer 2 (1), 15, 2007 | 97 | 2007 |
| A multi-type HPV transmission model EH Elbasha, EJ Dasbach, RP Insinga Bulletin of mathematical biology 70 (8), 2126-2176, 2008 | 94 | 2008 |
| Deadweight loss of bacterial resistance due to overtreatment EH Elbasha Health economics 12 (2), 125-138, 2003 | 84 | 2003 |
Salaheddin MahmudProfessor and Canada Research Chair of Pharmaco-epidemiology, University of ManitobaVerified email at mcgill.ca
